Literature DB >> 11128838

Myasthenia gravis in a collegiate football player.

J J Leddy1, J G Chutkow.   

Abstract

A 17-yr-old Division I-AA collegiate offensive lineman developed unilateral ptosis shortly after minor head trauma during a scrimmage. The subsequent temporal profile of the ptosis, a history of a similar event lasting a short period of time 2 yr earlier, and the results of his clinical and electrophysiologic examinations established a diagnosis of very mild, generalized, antibody-negative myasthenia gravis (MG). His desire to continue playing football posed several additional management problems for which there was no published guidance. We started him on alternate-day, high-dose prednisone therapy with potassium and calcium supplementation, and allowed him to partake in conditioning but no contact. Except for residual decreased exercise tolerance, he improved symptomatically and experienced no serious adverse effects from the illness or the treatment during his first season, despite imperfect drug compliance. His MG eventually came under excellent symptomatic control, allowing initiation of a slow taper of the prednisone before his second season. Shortly thereafter, he abruptly stopped the prednisone without seeking medical advice. He continued to experience mild left ptosis and a mild decrease in intense exercise tolerance. He decided to forego his senior season of collegiate football after a bout of severe mechanical low-back pain incurred during spring football practice and limited his athletic activity thereafter to recreational sports.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128838     DOI: 10.1097/00005768-200012000-00001

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  2 in total

1.  The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial.

Authors:  Simone Birnbaum; Jean-Yves Hogrel; Raphael Porcher; Pierre Portero; Bernard Clair; Bruno Eymard; Sophie Demeret; Guillaume Bassez; Marcela Gargiulo; Estelle Louët; Sonia Berrih-Aknin; Asmaa Jobic; Philippe Aegerter; Philippe Thoumie; Tarek Sharshar
Journal:  Trials       Date:  2018-01-18       Impact factor: 2.279

2.  Marathons and myasthenia gravis: a case report.

Authors:  Simone Birnbaum; Tarek Sharshar; Bruno Eymard; Marie Theaudin; Pierre Portero; Jean-Yves Hogrel
Journal:  BMC Neurol       Date:  2018-09-18       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.